Summary
A bioRxiv preprint links CXCR6-positive tissue-resident CD4 memory T cells with response to immune checkpoint inhibition in a glioma model. Analysis of patient tumour tissue also found an association with longer overall survival.
A bioRxiv preprint reports that CXCR6-positive tissue-resident memory CD4 T cells are associated with response to immune checkpoint inhibition in high-grade glioma. The researchers identified this pattern in a syngeneic hypermutated tumour model treated with combined PD-1 and CTLA-4 inhibition, then examined tissue from patients with IDH1-wildtype glioblastoma who received pembrolizumab before surgery. In the patient tissue analysis, CD4 T cells showed increased CXCR6 expression, and the presence of CD4 tissue-resident memory cells was associated with longer overall survival.
The work points to a possible role for CD4 T cells alongside the better-studied tumour-killing CD8 T cells. It is a preprint, and its patient findings are associations from tissue analysis rather than evidence that these cells cause longer survival.
How the researchers identified the response pattern
The team compared tumour-infiltrating T cells from responding and non-responding tumours in the model using single-cell RNA sequencing and T-cell receptor sequencing. The first method profiles gene activity in individual cells; the second helps identify T-cell clones that share a receptor. The researchers also functionally tested tumour-reactive receptor clones.
In responding tumours, they found clonal expansion of tumour-reactive cytotoxic T cells and greater infiltration of CXCR6-positive CD4 tissue-resident memory T cells. These memory cells are characterised by remaining within tissues rather than circulating mainly through the blood. CD4 stem-like memory T cells in responding tumours showed stronger interferon-response activity. The researchers’ inferred cell-state trajectories led towards clonally expanded tissue-resident memory cells in responders, while trajectories in non-responders led towards exhaustion, a state in which immune cells have reduced function.
The study also describes interactions between CD4 tissue-resident memory cells and CXCR3-positive, tumour-reactive cytotoxic T cells in responding tumours. Those cytotoxic cells had expanded clonally but retained varied gene-expression states. Together, the observations suggest a coordinated immune response rather than a single cell type acting alone. PD-1 and CTLA-4 are immune checkpoint proteins; blocking them can release inhibitory controls on immune activity.
What the patient tissue analysis adds
The researchers examined tissue from patients with IDH1-wildtype glioblastoma treated with neoadjuvant pembrolizumab, an anti-PD-1 drug given before surgery. They report increased CXCR6 expression in CD4 T cells and an association between CD4 tissue-resident memory cells and prolonged overall survival. This makes the model findings relevant to human disease, while the survival result remains an association and does not show that the cells themselves extended patients’ lives.
The study therefore identifies CD4 tissue-resident memory cells as a candidate feature of glioma response to checkpoint inhibition. Whether measuring these cells can help predict treatment response, or whether therapies that alter them can improve outcomes, will require further investigation.